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Abstract : Lung cancer is the leading cause of malignancy-related death worldwide. In
the present study, we reviewed the epidemiologic and clinical features of lung cancer in
Tokushima Prefecture, Japan. Between January 1999 and December 2009, 2,183 patients
with lung cancer were enrolled in this study. One thousand five hundred ninety-one (73%)
patients were male and 592 (27%) patients were female. Median age was 70 years, with a
range of 15-93 years. Seventy-six percent of patients had smoking history. One thousand
nine hundred five (87%) patients were non-small cell lung cancer and the predominant his-
tological type was adenocarcinoma (51%). Among all 2,183 patients, 702 (32%) belonged to
elderly population. Four hundred seventy-one (22%), 213 (10%), 24 (1%), 116 (5%), 238 (11%),
370 (17%) and 678 (31%) patients had stage IA, IB, IIA, IIB, IIIA, IIIB and IV lung cancer, re-
spectively. In Tokushima University Hospital, 516 (29%), 191 (11%), 58 (3%), 755 (43%) and
216 (12%) patients were initially treated with chemotherapy, chemo-radiotherapy, tho-
racic radiotherapy, operation and best supportive care, respectively. The median time to
progression (TTP) and the median survival time (MST) of patients treated with chemother-
apy and chemo-radiotherapy were 3.5 months, 13.0 months and 7.0 months, 18.0 months,
respectively. The median TTP and the MST of 33 elderly patients treated with chemother-
apy were 3.3 months and 18.0 months, respectively, which were comparable with those of
total population. These results indicated the benefit of chemotherapy in elderly patients
with advanced lung cancer by proper selection. J. Med. Invest. 57 : 326-333, August, 2010
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INTRODUCTION
Lung cancer is a global public health problem of
epidemic proportions, and the number of people af-
fected is expected to grow in the near future (1). De-
spite improvements in survival for many other types
of cancer in recent years, 5-year survival for lung
cancer has remained relatively poor, mainly because
by the time a diagnosis is made, lung cancer is fre-
quently advanced and treatment options are limited
(2-4).
An estimated 1.35 million people were newly di-
agnosed with lung cancer worldwide in 2002 (12.4%
of all new cancers) (5), an increase of about 110,000
compared with the number in 2000 (6). In addi-
tion, lung cancer is the leading cause of malig-
nancy-related death worldwide (5). In 2002 there
were about 1.18 million deaths caused by lung can-
cer internationally (5), an increase of over 70,000
deaths since 2000 (6). Lung cancer deaths caused
almost 18% of total cancer mortality (5, 7), and
around 2% of all mortality worldwide during 2002
(7).
Lung cancer is, to a major extent, a disease of the
elderly (8). The prevalence and societal burden of
this disease will increase as more people survive
into old age. Elderly patients with cancer are signifi-
cantly under-represented in all clinical trials, includ-
ing in those for lung cancer (9-11). A retrospective
analysis of all patients enrolled onto Southwest On-
cology Group trials between 1993 and 1996 dem-
onstrated that only 25% were 65 years or older,
whereas this age subgroup made up 63% of the U.S.
population of patients with cancer (11). The low en-
rollment of patients older than 70 years was largely
responsible for this discrepancy (11).
In Japan, 62,063 (45,189 male and 16,874 female)
patients died of lung cancer, which consisted of 19%
of all malignancy-related death in 2005, and more
than half of them (53%) belonged to 75 years or
older, so-called elderly patient population (12).
Tokushima Prefecture, a regional area located in
southeast part of Shikoku Island, Japan, had 459
(342 male and 117 female) patients who died of lung
cancer in 2005, and inclined to have more elderly
patients (58%) than all parts of Japan (12).
While the outlines of epidemiology of lung cancer
have been reported as mentioned above, detailed
epidemiologic and clinical trends in Tokushima Pre-
fecture still remain uncertain. In the present study,
we reviewed the epidemiology of lung cancer in
Tokushima Prefecture focusing on 1) the incidence
by age and histology, and 2) stage, treatment mo-
dalities and clinical outcome in comparison between
elderly patient and younger or total populations.
PATIENTS AND METHODS
Patient eligibility
The patients who had been either cytologically
or histologically confirmed to have lung cancer in
Tokushima University Hospital and Tokushima Pre-
fectural Central Hospital from 1999 to 2009 were eli-
gible for this retrospective study. Tokushima Uni-
versity Hospital and Tokushima Prefectural Central
Hospital are two main hospitals engaging in lung
cancer treatment in Tokushima Prefecture and more
than 50% of lung cancer patients in Tokushima Pre-
fecture were treated in these two hospitals. There-
fore, we considered that patient population in these
two hospitals was able to recapitulate the epidemi-
ology of lung cancer in Tokushima Prefecture. We
defined 74 years or younger patients as younger
population and 75 years or older patients as elderly
population. The study protocol was approved by the
Institutional Review Board of each of the participat-
ing institution.
Evaluation of response and toxicity for treatment
Enrolled patients were appropriately treated with
standard treatment modalities for lung cancer de-
pending on their general status. Chest X-ray, com-
plete blood count, and blood chemistry studies were
repeated at least once a month for follow-up. The
response was assessed based on the computed to-
mography scan findings that initially had been used
to define the tumor extent. The response was evalu-
ated in accordance with the Response Evaluation
Criteria in Solid Tumors version 1.0.
Statistical analysis
For the evaluation of the efficacy of chemother-
apy, we investigated the time to progression (TTP)
and overall survival (OS) of lung cancer patients who
received any chemotherapeutic agents in Tokushima
University Hospital. The TTP was defined as the
time from diagnosis to progression or death from
any cause. The OS was defined as the time from di-
agnosis to death from any cause or when last known
to be alive. The TTP and the OS were estimated by
the Kaplan-Meier method of univariate analysis. The
differences between categorized groups were com-
pared by the One-way ANOVA test. All statistical
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tests were two sided, and values of p0.05 were
considered to indicate statistical significance.
RESULTS
Patient population
Between January 1999 and December 2009, 2,183
patients with lung cancer from 2 institutions were
enrolled in this study. The clinical characteristics of
all 2,183 patients are listed in Table 1. One thousand
five hundred ninety-one (73%) patients were male
and 592 (27%) patients were female. Median age
was 70 years, with a range of 15-93 years. Seventy-
six percent of all 2,183 patients had smoking history.
Causes for detection of lung cancer were as follows ;
medical screening (21%), symptom related to lung
cancer (55%), examination during follow-up of other
diseases (24%). Non-small cell lung cancer (NSCLC)
and small cell lung cancer (SCLC) constituted 87%
and 13% of all lung cancer patients, respectively.
With regard to NSCLC, the predominant histologi-
cal type was adenocarcinoma (51%) followed by
squamous cell carcinoma (25%), large cell carci-
noma (3%) and others (8%).
As shown in Table 2, 471 (22%), 213 (10%), 24
(1%), 116 (5%), 238 (11%), 370 (17%) and 678 (31%)
patients had stage IA, IB, IIA, IIB, IIIA, IIIB and IV
lung cancer, respectively. In NSCLC, 783 (41%) and
1,060 (56%) patients had early (IA, IB, IIA and IIB)
and advanced (IIIA, IIIB and IV) stages, respec-
tively. In SCLC, 133 (48%) patients had distant me-
tastasis, which was consistent with previous report
(13). Among all 2,183 patients, 1,481 (68%) and 702
(32%) belonged to younger and elderly population,
respectively. There was no significant difference in
stage distribution between younger and elderly
population in NSCLC, SCLC and total lung cancer.
Treatment modalities and patient survival
Next, we analyzed the first-line treatment modali-
ties in 1,763 patients who were initially treated in
two participating institutions. Five hundred sixteen
(29%), 191 (11%), 58 (3%), 755 (43%) and 216 (12%)
patients were treated with chemotherapy, chemo-
radiotherapy, thoracic radiotherapy, operation and
best supportive care, respectively. As expected, there
was remarkable difference of initial treatment among
histological subtypes of lung cancer, namely, opera-
tion was undergone in almost half (48%) of NSCLC
patients, while SCLC patients were predominantly
treated with chemotherapy (60%).
Table 1. Patient characteristics
No. 2,183
Age (Year)
Median (Range) 70 (15-93)
Gender
Male 1,591 (73%)
Female 592 (27%)
Histology
Non-small cell lung cancer 1,905 (87%)
Adenocarcinoma 1,112 (51%)
Squamous cell carcinoma 545 (25%)
Large cell carcinoma 69 ( 3%)
Others 179 ( 8%)
Small cell lung cancer 278 (13%)
Table 2. Comparison of clinical stages for lung cancer between younger and elderly patients.
Stage
Number of patients (%)
NSCLC SCLC Total
Younger Elderly Total Younger Elderly Total Younger Elderly Total
IA 303(23) 146 (24) 449 (24) 11 ( 6) 11 (12) 22 ( 8) 314 (21) 157 (22) 471 (22)
IB 125(10) 82 (13) 207 (11) 4 ( 2) 2 ( 2) 6 ( 2) 129 ( 9) 84 (12) 213 (10)
IIA 16( 1) 7 ( 1) 23 ( 1) 1 ( 1) 0 ( 0) 1 ( 0) 17 ( 1) 7 ( 1) 24 ( 1)
IIB 62( 5) 42 ( 7) 104 ( 5) 8 ( 4) 4 ( 4) 12 ( 4) 70 ( 5) 46 ( 7) 116 ( 5)
IIIA 142(11) 66 (11) 208 (11) 21 (11) 9 (10) 30 (11) 163 (11) 75 (11) 238 (11)
IIIB 202(16) 105 (17) 307 (16) 43 (23) 20 (22) 63 (23) 245 (17) 125 (18) 370 (17)
IV 408(32) 137 (22) 545 (29) 94 (51) 39 (42) 133 (48) 502 (34) 176 (25) 678 (31)
unstaged 37( 3) 25 ( 4) 62 ( 3) 4 ( 2) 7 ( 8) 11 ( 4) 41 ( 3) 32 ( 5) 73 ( 3)
Total 1,295 610 1,905 186 92 278 1,481 702 2,183
NSCLC : non-small cell lung cancer, SCLC : small cell lung cancer
younger : 74 years or younger patients, elderly : 75 years or older patients
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Among 1,763 patients, 1,218 (69%) and 545 (31%)
belonged to younger and elderly population, respec-
tively. We compared the initial treatment modali-
ties for lung cancer among these populations. The
proportions of NSCLC patients treated with opera-
tion and that of SCLC patients treated with chemo-
therapy were comparable between younger and
elderly population (48% in younger, 47% in elderly
and 59% in younger, 61% in elderly, respectively).
On the other hand, the proportion of patients treated
with chemo-radiotherapy tended to be lower in eld-
erly than younger population (5% vs. 11% in NSCLC
(p=0.13), 11% vs. 27% in SCLC (p=0.06) and 6% vs.
13% in total lung cancer (p=0.12), respectively), and
that of patients treated with best supportive care
tended to be higher in elderly than younger popu-
lation (25% vs. 8% in NSCLC (p=0.08), 13% vs. 3%
in SCLC (p=0.18) and 23% vs. 7% in total lung can-
cer (p=0.09), respectively), while these differences
were not significant (Table 3).
Finally, we evaluated the survival of the subgroup
underwent chemotherapy in Tokushima University
Hospital. Between January 1999 and December
2009, 204 and 84 patients with NSCLC were treated
with chemotherapy, chemo-radiotherapy, respec-
tively. The median TTP and the median survival
time (MST) of patients treated with chemotherapy
and chemo-radiotherapy were 3.5 months, 13.0
months and 7.0 months, 18.0 months, respectively
(Fig. 1 and 2). Among 204 NSCLC patients treated
with chemotherapy, 33 (16%) belonged to elderly
population. The median TTP and the MST of 33
elderly patients treated with chemotherapy were
3.3 months and 18.0 months, respectively (Fig. 3),
which were comparable with those of total popula-
tion.
Table 3. Comparison of treatment modalities for lung cancer between younger and elderly patients.
Treatment
Number of patients (%)
NSCLC SCLC Total
Younger Elderly Total Younger Elderly Total Younger Elderly Total
Chemotherapy 311 (29) 71 (15) 382 (25) 90 (59) 44 (61) 134 (60) 401 (33) 115 (21) 516 (29)
Chemo-radiotherapy 116 (11) 26 ( 5) 142 ( 9) 41 (27) 8 (11) 49 (22) 157 (13) 34 ( 6) 191 (11)
Thoracic radiotherapy 17 ( 2) 36 ( 8) 53 ( 3) 2 ( 1) 3 ( 4) 5 ( 2) 19 ( 2) 39 ( 7) 58 ( 3)
Operation 513 (48) 221 (47) 734 (48) 14 ( 9) 7 (10) 21 ( 9) 527 (43) 228 (42) 755 (43)
Best supportive care 87 ( 8) 116 (25) 203 (13) 4 ( 3) 9 (13) 13 ( 6) 91 ( 7) 125 (23) 216 (12)
Others 22 ( 2) 3 ( 1) 25 ( 2) 1 ( 1) 1 ( 1) 2 ( 1) 23 ( 2) 4 ( 1) 27 ( 7)
Total 1,066 473 1,539 152 72 224 1,218 545 1,763
NSCLC : non-small cell lung cancer, SCLC : small cell lung cancer
younger : 74 years or younger patients, elderly : 75 years or older patients
Figure 1. The survival of NSCLC patients treated with che-
motherapy.
The survival of 204 NSCLC patients treated with chemotherapy
was calculated according to the Kaplan-Meier method. The me-
dian TTP and MST were 3.5 months and 13.0 months, respec-
tively.
Figure 2. The survival of NSCLC patients treated with chemo-
radiotherapy.
The survival of 84 NSCLC patients treated with chemo- radio-
therapy was calculated according to the Kaplan-Meier method.
The median TTP and MST were 7.0 months and 18.0 months,
respectively.
The Journal of Medical Investigation Vol. 57 August 2010 329
DISCUSSION
Lung cancer has been the most common cancer
in the world since 1985 (14), and by 2002, there
were 1.35 million new cases, representing 12.4% of
all new cancers. It was also the most common cause
of death of cancer, with 1.18 million deaths, or
17.6% of the world total. The prognosis for people
diagnosed with lung cancer remains poor world-
wide, with 5-year relative survival typically between
6 to 14% among males and 7 to 18% among females
(15).
The incidence and mortality of lung cancer are
very much influenced by past exposure to tobacco
smoking (16). For the year 2000, an estimated 85%
of lung cancer in men and 47% of lung cancer in
women is the consequence of tobacco smoking. A
higher proportion of lung cancer deaths were attrib-
utable to smoking than for any other disease (17).
It has been estimated that nearly three quarters
(71%) of lung cancer deaths worldwide were caused
by smoking in 2000 (17). By 2015, this would result
in a projected 1.18 million smoking related lung
cancer deaths per year (7). In this study, 76% of
lung cancer patients had smoking history, indicat-
ing that the high prevalence of tobacco smoking in
Tokushima Prefecture was closely related to the
occurrence and morbidity of lung cancer in consis-
tent with previous reports.
Lung cancer is, to a major extent, a disease of the
elderly (8). The prevalence and societal burden of
this disease will increase as more people survive
into old age. Given that the population older than
65 years constitutes the fastest-growing segment
and is projected to double by the year 2030 (18),
elderly lung cancer patients are anticipated to be
going to increase hereafter. Worldwide during 2002,
5% of lung cancer cases were diagnosed among
people aged 0 to 44 years, 14% in the 45 to 54 age
group, 25% in the 55 to 64 age group, and 55%
among those aged 65 years and over (19). In all
parts of Japan and Tokushima Prefecture, 33,165 and
265 elderly (75 years or older) patients died of lung
cancer in 2005, respectively. The proportions of eld-
erly patients in all parts of Japan and Tokushima
Prefecture constituted 53% and 58% of all lung can-
cer-related death, respectively (12), suggesting that
around half of lung cancer patients belonged to
elderly population in Japan. In the present study,
32% (702/2,183) of lung cancer patients was elderly
population. As Tokushima University Hospital and
Tokushima Prefectural Central Hospital are highly
specified hospitals to the intensive cancer treatment,
advanced lung cancer patients who are considered
to be intolerable to intensive treatment owing to
poor performance status and/or high age tend to
be avoided for referral to our two institutions by
primary doctors. Therefore, the discrepancy of the
Figure 3. The survival of elderly NSCLC patients treated with chemotherapy.
The survival of 33 elderly NSCLC patients treated with chemotherapy was calculated according to the Kaplan-Meier method. The
median TTP and MST were 3.3 months and 18.0 months, respectively.
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proportion of elderly patient population between
previous reports and our study might be explained
by the under-estimation of the number of elderly
lung cancer patients in the present study.
According to cancer registry data in National
Cancer Center, Japan (12), age-standardized lung
cancer mortality rates (per 100,000) in 2005 were
comparable between all parts of Japan (15.63) and
Tokushima Prefecture (15.57). But Tokushima Pre-
fecture had a tendency to have more elderly patients
who died of lung cancer than all parts of Japan. The
proportions of elderly patients in total population,
male and female were 53% and 58%, 51% and 55%,
and 60% and 67% in all parts of Japan and Tokushima
Prefecture, respectively (Table 4). These epidemi-
ologic data might reflect the trend that elderly popu-
lation in Tokushima Prefecture had been growing
faster than cross-sectional population of Japan.
In the present study, there was no difference in
the proportion of NSCLC patients initially treated
with operation between younger and elderly popu-
lation (48% and 47%, respectively), suggesting that
operation could be actively performed even in eld-
erly lung cancer patients after consideration for its
indication. Similarly, the proportion of SCLC patients
treated with chemotherapy was also comparable
between younger and elderly population (59% and
61%, respectively), reflecting the fact that SCLC is
characterized by significant sensitivity to initial che-
motherapy (20). On the other hand, the proportion
of patients initially treated with chemo-radiotherapy
tended to be lower in elderly than younger popula-
tion (5% vs. 11% in NSCLC, 11% vs. 27% in SCLC
and 6% vs. 13% in total lung cancer, respectively),
and that of patients initially treated with best sup-
portive care tended to be higher in elderly than
younger population (25% vs. 8% in NSCLC, 13% vs.
3% in SCLC and 23% vs. 7% in total lung cancer,
respectively), while these differences were not sig-
nificant (Table 3). Elderly lung cancer patients com-
monly have poor performance status and higher
incidence of smoking-related comorbidities, such as
cardiovascular diseases, chronic pulmonary emphy-
sema, pulmonary fibrosis and so on. These factors
might lead to the physician’s discretion to avoid
aggressive anti-cancer treatment in these patients.
A number of randomized clinical trials support
the conclusion that the combined modality of che-
motherapy and radiotherapy improve survival com-
pared with either chemotherapy or radiotherapy
alone for locally advanced NSCLC (21, 22). The re-
sponse rate (RR) and MST in the phase III trials
that use chemo-radiotherapies have been reported
to be 49-84% and 14.5-16.5 months, respectively (23,
24). In this study, the MST of 84 patients treated
with chemo-radiotherapy was 18.0 months, which
was comparable with previous phase III studies.
The standard chemotherapy regimen for ad-
vanced NSCLC is considered to be two-drug com-
bination chemotherapy with platinum agents and
new-generation non-platinum antitumor agents,
such as paclitaxel, docetaxel, gemcitabine, and vi-
norelbine. The RR, TTP and MST in the phase III
trials that use these combination chemotherapies
have been reported to be 17-28%, 3-4 months and
7-9 months, respectively (25-27). In this study, the
Table 4. Comparison of epidemiologic trends of lung cancer between all parts of Japan and Tokushima Prefecture in 2005.
Population
Lung cancer-related death
ASRYounger Elderly Total
No. (%) No. (%) No. (%)
Total
Japan 28,898 (47) 33,165 (53) 62,063 (100) 15.63
Tokushima 194 (42) 265 (58) 459 (100) 15.57
Male
Japan 22,196 (49) 22,993 (51) 45,189 (100) 24.97
Tokushima 155 (45) 187 (55) 342 (100) 26.49
Female
Japan 6,702 (40) 10,172 (60) 16,874 (100) 7.13
Tokushima 39 (33) 78 (67) 117 (100) 5.88
cited from reference 12
younger : 74 years or younger patients, elderly : 75 years or older patients
ASR : age-standardized lung cancer mortality rate (per 100,000)
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median TTP and the MST of patients treated with
chemotherapy were 3.5 months, 13.0 months, re-
spectively, in consistent with previous phase III stud-
ies. Moreover, it is noteworthy that the median TTP
and the MST of 33 elderly patients treated with
chemotherapy were shown to be 3.3 months, 18.0
months, respectively, which were comparable with
those of total population. These results indicated the
significant findings that chemotherapy had survival
benefit even in elderly patients if they were prop-
erly selected for the indication of chemotherapy.
Further studies should be warranted to elucidate
the therapeutic efficacy and safety of chemotherapy
in elderly patients with advanced NSCLC.
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